^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AU-101

i
Other names: AU-101, AU101, AU 101, Autologous HER2-specific T cells, HER2-specific T cells, HER2 chimeric antigen receptor expressing T cell therapy, HER2-CART
Associations
Company:
Aurora Biopharma, Baylor College of Medicine
Drug class:
HER2-targeted CAR-T immunotherapy, CD28-targeted CAR-T immunotherapy
Associations
over1year
iCAR: T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=28 --> 10 | Trial completion date: Jan 2036 --> Apr 2037
Enrollment closed • Enrollment change • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression
|
AU-101
over3years
iCAR: T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (clinicaltrials.gov)
P1, N=28, Recruiting, Baylor College of Medicine | Trial completion date: Jan 2031 --> Jan 2036 | Trial primary completion date: Feb 2021 --> Feb 2026
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression
|
AU-101
4years
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (clinicaltrials.gov)
P1, N=36, Active, not recruiting, Baylor College of Medicine | Trial primary completion date: Jul 2020 --> Dec 2019
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression
|
fludarabine IV • AU-101 • cyclophosphamide intravenous
over4years
iCAR: T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (clinicaltrials.gov)
P1, N=28, Recruiting, Baylor College of Medicine | Trial primary completion date: Feb 2020 --> Feb 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression
|
AU-101
almost5years
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (clinicaltrials.gov)
P1, N=36, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression
|
fludarabine IV • AU-101 • cyclophosphamide intravenous